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Abstract. Background: Aberrant activation of the canonical
Wingless-type MMTV integration site family (WNT)/β-catenin
signaling pathway is critical for gliomas. Materials and
Methods: In 74 gliomas of different histological grade and in
24 glioblastoma cell lines, protein expression of WNT member
3a (WNT3a), β-catenin and transcription factor 4 (TCF4) was
investigated by immunohistochemistry, western blotting,
immunofluorescence and immunocytochemistry. In tumors and
cell lines, WNT3A expression was assessed at the mRNA level
by quantitative real-time polymerase chain reaction. Results:
WNT3a was overexpressed at the protein and mRNA levels in
malignant astrocytic tumors and cell lines. Cytoplasmic
expression of β-catenin was detected in high-grade gliomas
and cell lines, with evidence of nuclear translocation on
fractionated protein extracts. Activating mutations in the β-
catenin encoding gene (CTNNB1) were excluded by direct
sequencing. TCF4 was statistically correlated with Ki-67/MIB-
1 and cyclin D1 labeling indices. Conclusion: Expression of
WNT3a, cytoplasmic β-catenin and TCF4 was significantly
associated with the histological malignancy grade and with a
worse prognosis for patients with glioma.
The Wingless-type MMTV integration site family (WNT)
signaling pathway is involved in different biological processes,
such as embryonic development, cell polarity, fate and tissue
homeostasis (1). The β-catenin (CTNNB1)-dependent pathway
(often referred as “canonical”) includes β-catenin and
transcription factor 4 (TCF4) as the key effectors and is
reported as an important factor in the development and
progression of several human cancer types (2-6). 
The signaling transduction cascade is triggered by the binding
of WNT ligands to Frizzled (Fz) protein and to low-density
lipoprotein receptor-related proteins 5/6 (LRP5/6), followed by
cytoplasmic β-catenin accumulation and subsequent nuclear
translocation. In the nucleus, β-catenin binds to members of the
TCF/lymphoid-enhancer-binding factor (LEF) family of
transcription factors and modulates expression of target genes
critical for cell proliferation, differentiation, survival and
apoptosis, such as cyclin D1, AP-1 transcription factor (FRA1),
V-MYC avian myelocytomatosis viral oncogene homolog (c-
MYC), V-JUN avian sarcoma virus 17 oncogene homolog (c-
JUN) and survivin (7, 8). In contrast, in the absence of WNT
ligands, β-catenin is constantly sequestrated within a degradation
complex composed of axin, tumor-suppressor adenomatous
polyposis coli (APC), casein kinase Iα (CKIα) and glycogen
synthase kinase-3β (GSK-3β) proteins. Upon phosphorylation
by CKIα and GSK-3β, β-catenin is polyubiquitinated for the
proteasomal degradation (Figure 1) (9). 
The aberrant activation of the canonical WNT/β-catenin
signaling pathway contributes to glioma development and
malignant progression (10-15), as well as invasion (16) with
prognostic implications (17-19). Among the WNT ligands
present in neuronal stem cells, WNT3a increases proliferation
and differentiation of neuronal progenitor cells in adult mice
brain (20, 21) and it is required for the development of the
mammalian hippocampus (22). Previous reports showed
overexpression of WNT1 and WNT3a in glioblastoma
multiforme and glioma stem cells, demonstrating pathway
activation in the malignant transformation and progression of
high-grade gliomas (23-25).
Compared to the normal brain, β-catenin and TCF4 are
up-regulated in gliomas, while knock-down of β-catenin in
human glioma cells by small interfering RNA (siRNA)
inhibits cell proliferation and invasive ability, induces
apoptotic cell death and delays tumor growth (26, 27). β-
Catenin protein levels increase in high-grade astrocytomas
and correlate with malignancy and with the gene expression
of cyclin D1 and c-MYC (10-12, 18, 28). 
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In the absence of WNT ligands, the oncogenic activation of
β-catenin may result from genetic mutations affecting key
components of the canonical pathway [APC, β-catenin-
encoding gene (CTNNB1), axin] (29). Activating mutations in
the CTNNB1 oncogene contribute to neoplastic transformation
in several types of human cancer, such as medulloblastoma,
hepatocellular carcinoma, colon and ovarian cancer, with the
common halimark of nuclear accumulation of β-catenin (30-
33). Unlike other malignancies, however, genetic events in
high-grade glioma are rare (14, 31, 34).
Finally, the WNT/β-catenin signaling pathway is involved
in the maintenance of tumor stem cells by inhibiting
differentiation, conditioning radio- and chemoresistance, and
inducing an invasive phenotype in gliomas (35-40). 
The aim of the present study was to verify the activation of
the canonical pathway by determining the expression of the key
players WNT3a, β-catenin and TCF4, in a series of 74
astrocytic and oligodendroglial gliomas and 24 glioblastoma
cell lines. We also studied the relationships of the WNT/β-
catenin signaling pathway with malignancy and the correlation
of TCF4 with cell proliferation and cyclin D1 expression.
Materials and Methods 
Brain tumor specimens. A total of 74 adult human brain tumors (31
glioblastomas and 43 grade I-III gliomas) were analyzed. All cases
were operated on at the Neurosurgery Unit of CTO Hospital/Health
and Science City (Turin, Italy). Surgical tumor specimens, from
either total or partial removal, were split into three consecutive
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Figure 1. Overview of the canonical Wingless-type MMTV integration site family (WNT)/β-catenin signaling. In the absence of WNT signal, β-
catenin is captured by adenomatous polyposis coli (APC) and axin within a destruction complex, phosphorylated (P) by casein kinase Iα (CKIα) and
glycogen synthase kinase-3β (GSK-3β) and targeted for ubiquitination (Ub) and proteasomal degradation. Transcription by transcription
factor/lymphoid-enhancer-binding factor (TCF/LEF) is off due to the binding of repressors. A pool of β-catenin is engaged in the interactions with
cadherins for cell–cell adhesion. The binding of WNT3a ligand to frizzled and low-density lipoprotein receptor-related proteins 5/6 (LRP5/6) co-
receptors determines the inactivation of the destruction complex. This allows β-catenin to accumulate in the cytoplasm and translocate to the nucleus,
where it forms a transcriptionally active complex with TCF/LEF family members.
fragments. The first one was formalin fixed, paraffin embedded
(FFPE) and cut into 5 μm-thick sections. The second one was
minced and enzymatically dissociated for expansion in culture, and
the third fragment was stabilized in RNAlater® solution (Thermo
Fisher Scientific Inc., Waltham, MA, USA) and stored at −80˚C for
molecular genetics and proteins. Two brain samples from the
periventricular region were obtained from patients with epilepsy
and diagnosed as normal nervous tissue. The histological diagnosis
was performed according to the World Health Organization (WHO)
guidelines (41). Matched constitutional DNA from blood/saliva was
obtained from each patient. Patient demographics are summarized
in Table I. 
Ethics statement. Human brain specimens for molecular genetics,
proteins and cultures were obtained and used in compliance with
the local Institutional Review Board and Committee on Human
Research and with the ethical human subject principles of the World
Medical Association Declaration of Helsinki Research. Written
informed consent was obtained from all patients after ethics
approval of the CTO Hospital/Health and Science City, Turin, Italy
(n. 487/2012). 
Immunohistochemistry. In addition to hematoxylin and eosin
(H&E) staining, immunohistochemistry was performed with the
primary antibodies listed in Table II on a Ventana Full BenchMark®
XT automated immunostainer (Ventana Medical Systems Inc.,
Tucson, AZ, USA). Ultra-View™ Universal DAB and Alkaline
Phosphatase Red Detection Kits were used for visualization of
antibody reactions (Ventana Medical Systems Inc.). Heat-induced
epitope retrieval (HIER) was obtained with Tris–EDTA (pH 8).
CD34 immunostaining was used to distinguish isolated endothelial
cells from tumor cells.
In vitro cultures. A total of 24 glioblastoma cell lines were
established from glioblastoma tumors removed at the Neurosurgery
Unit of CTO Hospital/Health and Science City of Turin, Italy.
Culture conditions have been previously described (42, 43). Nine
cell lines (CV13 NS, CV21 NS, NO3 NS, NO6 NS, CTO3 NS,
CTO11 NS, CTO12 NS, CTO15 NS, CTO22 NS) were isolated in
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 supplemented
with 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml basic
fibroblast growth factor (bFGF) for the neurosphere (NS) assay.
Thirteen cell lines (CV2 AC, CV6 AC, CV8 AC, CV9 AC, CV10
AC, CV21 AC, NO3 AC, NO4 AC, CTO3 AC, CTO15 AC, CTO16
AC, CTO20 AC, CTO21 AC) were developed in DMEM with 10%
fetal bovine serum (FBS) for conventional monolayer growth and
named adherent cells (AC). Both types of cultures were maintained
in a humidified atmosphere of 5% O2 and 5% CO2. 
Cell line authentication from the respective primary tumor was
obtained by short tandem repeat (STR) profiling. 
Two malignant glioma cell lines (U87 MG and 010627) were
kindly supplied by Dr. Rossella Galli (DIBIT San Raffaele, Milan,
Italy) and maintained as AC and NS, respectively.
All experiments on primary glioblastoma cell lines were carried
out with cells from passages 10-20. All cultures were checked for
Mycoplasma contamination before experimental use (e-Myco™
Mycoplasma PCR Detection kit; iNtRON Biotechnology Inc.,
Gyeonggi-do, South Korea).
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Table I. Patients’ demographics.
Tumor type WHO grading Patients (N) Gender (M/F) Mean age (years and range)
N=74
Pilocytic astrocytoma I 5 2/3 34 (19-66)
Diffuse astrocytoma II 8 2/6 30 (13-47)
Anaplastic astrocytoma III 12 7/5 60 (35-84)
Glioblastoma IV 31 23/8 63 (44-78)
Oligodendroglioma II 6 4/2 47 (34-59)
Anaplastic oligodendroglioma III 12 8/4 54 (36-64)
Table II. List of primary antibodies used for immunohistochemistry.
Antibody Source Dilution Code Manufacturer
Anti-Ki-67/MIB-1 Mouse 1:100 M7240 Dako Denmark A/S, Glostrup, Denmark
Anti-WNT3a* Mouse 1:100 NBP1-19050 Novus Biologicals, Littleton, CO, USA
Anti-β-catenin* Mouse 1:100 610153 BD Transduction Laboratories™, 
Franklin Lakes, New Jersey, USA
Anti-TCF4* Rabbit 1:100 30360002 Novus Biologicals, Littleton, CO, USA
Anti-phospho-β-catenin [Ser33/37/Thr41]* Rabbit 1:100 NBP1-19964 Novus Biologicals, Littleton, CO, USA
Anti-phospho-GSK-3β [Tyr216]* Rabbit 1:100 NB100-81946 Novus Biologicals, Littleton, CO, USA
Anti-cyclin D1 Mouse 1:200 15-MS-210-P0 NeoMarkers, Fremont, CA, USA
*Tested also by immunofluorescence and immunocytochemistry.
Immunofluorescence. Expression of key WNT/β-catenin pathway
molecules was examined on a panel of 12 glioblastoma cell lines
(seven NS and five AC). Cells were fixed for 20 min with 4%
paraformaldehyde at room temperature, rinsed three times with
phosphate-buffered saline (PBS), blocked/permeabilized for 30
minutes with 1× PBS containing 2% of the appropriate serum and
0.1% Triton X-100 and, finally, stained with the primary antibodies
listed in Table II. Negative controls were obtained by omitting the
primary antibody. Alexa Fluor® 488-AffiniPure goat anti-rabbit IgG
and Alexa Fluor® 594-AffiniPure rabbit anti-mouse IgG (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA, USA) were
used as secondary antibodies. Cell nuclei were stained with 4’,6-
diamidino-2-phenylindole (DAPI). Images were examined and
acquired on a Zeiss Axioskop fluorescence microscope (Karl Zeiss,
Oberkochen, Germany) equipped with an AxioCam5MR5c and
coupled to an imaging system (AxioVision Release 4.5, Zeiss). 
On CTO3 NS, CTO3 AC, NO3 NS and NO3 AC lines,
immunofluorescence was also carried out after treatment with 50 μM
temozolomide (Sigma Aldrich Co., St. Louis, MO, USA) for 48 h.
Immunocytochemistry. The analysis was performed using a Ventana
Full BenchMark® XT automated immunostainer (Ventana Medical
Systems Inc.) and UltraView™ Universal DAB Detection Kit
(Ventana Medical Systems Inc.) as detection system. HIER was
performed in Tris-EDTA (pH 8). Primary antibodies were the same
used for immunofluorescence with the same dilutions. Negative
controls were obtained by omitting the primary antibody. Images
were examined and acquired on a Zeiss Axioskop fluorescence
microscope. 
Protein extraction and western blotting analysis. Whole-protein
extracts from six cell lines as NS and six as AC were obtained using
a RIPA lysis buffer containing protease and phosphatase inhibitor
cocktails (Sigma Aldrich Co.). After protein quantification (BCA™
Protein Assay; Pierce Biotechnology, Rockford, IL, USA), 30 μg of
total protein extracts were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto polyvinylidene difluoride membranes (Immobilon-
P; Millipore, Bedford, MA, USA) with standard procedure. Primary
antibodies used were anti-WNT3a (NBP1-19050, dilution 1:1000;
Novus Biologicals, Littleton, CO, USA) and anti-β-catenin (610153,
dilution 1:500; BD Transduction Laboratories™, Franklin Lakes,
NJ, USA); secondary antibodies were horseradish peroxidase-
labeled (Dako, Glostrup, Denmark). Proteins were detected by
enhanced chemiluminescence using Immobilon Western reagents
(ECL; Millipore). A rabbit polyclonal antibody to human α-tubulin
(LF-PA0146, dilution 1:5,000; LabFrontier, Seoul, Korea) was used
to normalize sample loading and transfer. Band intensities were
quantified using NIH Image J software (National Institutes of
Health, Bethesda, MD, USA).
In order to analyze the subcellular localization of β-catenin,
nuclear and cytoplasmic fractions of frozen tissues and cells were
prepared using the NE-PER® Nuclear and Cytoplasmic Extraction
reagents (Pierce Biotechnology) as per manufacturer’s instruction.
Thirty micrograms of protein for cells and 50 μg for tissue analysis
were subjected to western blotting as described above, using
antibody to β-catenin. Antibody to human α-tubulin and an
anti–TATA-box binding protein (TBP/TFIID; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) were used as loading
controls for cytosolic and nuclear fractions, respectively.
DNA extraction. Genomic DNA (gDNA) from frozen or FFPE
tumor samples and cell lines was isolated using the QIAamp® DNA
Mini kit (Qiagen Inc., Valencia, CA, USA), according to the
manufacturer’s instructions. Constitutional gDNA was extracted
from peripheral blood by a salting-out protocol and from saliva
using the Oragene® DNA Collection kit (DNA Genotek Inc., ON,
Canada, USA).
CTNNB1 mutation analysis. CTNNB1 exon 3 encodes the N-terminal
regulatory sequence of the β-catenin protein that contains the
consensus phosphorylation sites for GSK-3β critical for its
proteasomal degradation. Two primer pairs designed on gDNA were
used to amplify CTNNB1 (GenBank reference sequence
NM_001098209) exon 3 and the adjacent splice sites (including at
least 100 bp of the flanking intronic sequences) by polymerase chain
reaction (PCR). The primer sequences are available on demand. PCR
amplification was performed in a total volume of 10 μl containing
50 mM KCl, 10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 250 μM of
each dNTP, 0.365 U of AB Taq Polymerase (AB Analitica, Padova,
Italy), 10 pmol of each primer and 50 ng of genomic DNA. A
standard touchdown PCR protocol was used.
Sanger direct sequencing. Prior to sequencing, PCR products were
purified by 0.5 U shrimp alkaline phosphatase (SAP) and 5 U
exonuclease I (GE Healthcare BioSciences, Auckland, New
Zealand), according to manufacturer’s instructions. Cycle
sequencing was performed using the BigDye® Terminator v1.1
Cycle Sequencing Kit (Thermo Fisher Scientific Inc.). Sequencing
products were analyzed by Sanger sequencing on an ABI® 3130
Genetic Analyzer and data collected by Sequencing Analysis v.5.3.1
software (Thermo Fisher Scientific Inc.).
RNA isolation and quantitative real-time PCR (qRT-PCR). Total
RNA from frozen tissues and cell lines was isolated using the
RNeasy® Mini Kit (Qiagen Inc.). One microgram of RNA was
reverse transcribed into cDNA using random primers with the High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific
Inc.), according to the manufacturer’s protocol. 
qRT-PCR for WNT3A was performed on a StepOne Real-Time
PCR system using the StepOne software v2.3 (Thermo Fisher
Scientific Inc.). Reactions were performed in triplicate using
TaqMan® Gene Expression Master Mix and TaqMan® Gene
Expression Assay (WNT3A Hs00263977_m1) (both from Thermo
Fisher Scientific Inc.). 
A suitable endogenous reference gene was validated by comparing
the stability of three different housekeeping genes [glyceraldehyde-
3-phosphate dehydrogenase (GADPH), beta-2-microglobulin (B2M)
and hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1)] in a
series of glioblastoma tumor specimens. Relative fold changes of
WNT3A gene expression were then normalized against that of the
endogenous HPRT1 gene and determined by calculation of the 2–ΔΔct.
A commercial FirstChoice® human brain total RNA (Ambion®,
Thermo Fisher Scientific Inc.) was used as reference and two normal
nervous tissues as internal control. 
Statistical methods. Associations between categorical variables were
evaluated using 2×2 contingency tables by the two-tailed Fisher’s
exact test. The Pearson’s correlation coefficient was used to examine
correlations among TCF4, cyclin D1 and Ki-67/MIB-1 labeling
indices (LIs).
CANCER GENOMICS & PROTEOMICS 13: 31-46 (2016)
34
Overall survival (OS) was defined as the time between the
histological diagnosis and patient’s death or last follow-up. Patients
alive at last follow-up were considered censored events. Survival
curves were estimated using the Kaplan–Meier method and
differences between them were compared by the log-rank test
(Mantel–Cox). Analysis was carried out by SPSS v21.0 software
(SPSS Inc., Chicago, IL, USA). p-Values <0.05 were considered as
statistically significant.
Results 
Immunohistochemistry. The immunohistochemical
demonstration of WNT3a expression was technically very
difficult because of its variability. However, WNT3a was
negative in the normal nervous tissue (Figure 2A),
occasionally and slightly positive on the cell membranes of
grade II and III oligodendrogliomas (Figure 2B), negative in
grade II and III astrocytomas (Figure 2C), whereas it was
highly expressed in the cytoplasm and on the cell membranes
of glioblastomas (Figure 2D). WNT3a expression was not
found in pilocytic astrocytomas.
β-Catenin was weakly expressed in the normal nervous
tissue only on the cell membranes (Figure 2E). It was
expressed in the cytoplasm and on the cell membranes more
intensely with increasing histological grade (Figure 2F-H).
The immunostaining intensity was higher and prevailingly
cytoplasmic in high- rather than in low-grade astrocytomas,
while it was limited to the cell membranes in
oligodendroglial tumors. β-Catenin expression was not found
in pilocytic astrocytomas. Clear-cut nuclear staining was not
found, with the exception of rare, scattered and barely
identifiable positive nuclei. In proliferative endothelial cells
of microvascular proliferation (MVPs), cytoplasmic and
membranous positive staining was diffusely present (Figure
2I). Occasionally, nuclear staining was detected, more
frequently and reliably compared to tumor cells (Figure 2J).
The cytoplasmic accumulation of β-catenin was regarded as
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Figure 2. Immunohistochemistry of Wingless-type MMTV integration site family (WNT)/β-catenin signaling pathway. A: Normal cortex. No WNT3a
expression, ×200. B: Grade II oligodendroglioma. Moderate WNT3a expression on the cell membranes, ×400. C: Grade II astrocytoma. No WNT3a
expression, ×400. D: Glioblastoma. Diffuse cytoplasmic and membranous WNT3a expression, ×400. E: Normal white matter. Slight membranous β-
catenin expression, ×200. F: Grade II oligodendroglioma. Diffuse membranous β-catenin expression, ×400. G: Grade III astrocytoma. Moderate
cytoplasmic and membranous β-catenin expression, ×400. H: Glioblastoma. High cytoplasmic and membranous β-catenin expression, ×400. I:
Glioblastoma. Cytoplasmic and membranous β-catenin expression in proliferative endothelial cells, ×200. J: Glioblastoma. Nuclear and cytoplasmic
β-catenin expression in hyperplastic endothelial cells, as indicated by arrows, ×630. K: Grade III astrocytoma. Granular expression of phospho-β-
catenin, ×200. L: Glioblastoma. Phospho-β-catenin expression in the cytoplasm of proliferative endothelial cells, ×200. M: Glioblastoma. Positivity
for phopsho-GSK-3β, ×200. All  specimens stained with 3,3' diaminobenzidine.
indicative of aberrant pathway activation. Phospho-β-catenin
(Ser33/37 /Thr41), considered as a destabilized and inactive
form of β-catenin, was variably expressed in all gliomas and
in endothelial cells with a granular staining pattern,
inversely correlated to the histological grade (Figure 2K and
L). Expression of phospho-GSK-3β (Tyr216), the active
form of GSK-3β in the degradation complex of β-catenin,
followed the immunostaining pattern of phospho-β-catenin
(Figure 2M). The frequency of WNT3a and β-catenin
immuno histochemical expression among gliomas of
different tumor types and histological malignancy grade is
reported in Figure 3.
TCF4 was expressed in nuclei of tumor cells, with a
variable staining intensity, and more in high- than in low-
grade gliomas (Figure 4A and B). Nuclei with the highest
staining intensity corresponded to those positive for Ki-
67/MIB-1 (r=0.761, p<0.0001) and cyclin D1 (r=0.739,
p<0.0001) (Figure 5). Nuclear cyclin D1 expression was
significantly higher in high- than in low-grade gliomas and
correlated with the Ki-67/MIB-1 LI (r=0.873, p<0.0001)
(Figure 4C and 5). By visual analysis of serial sections, the
areas with the maximum Ki-67/MIB-1 LI corresponded to
those positive for cyclin D1 and with the highest TCF4
expression (Figure 4D and E). Nuclei intensely positive for
TCF4 were also detected in proliferative endothelial cells
(Figure 4F). TCF4 expression was found neither in the
normal nervous tissue nor in pilocytic astrocytomas. 
Immunofluorescence. In NS, WNT3a was variably positive in
the cytoplasm (Figure 6A), β-catenin was more consistently
positive in the cytoplasm and on the cell membranes (Figure
6B), and TCF4 consistently positive in the nuclei (Figure 6C);
phospho-GSK-3β was variably positive in the cytoplasm
(Figure 6D). In AC, WNT3a was slightly positive, and β-
catenin and TCF4 negative in the cytoplasm, that, in contrast,
was positive for phospho-GSK-3β.
After treatment with 50 μM temozolomide for 48 h,
WNT3a, β-catenin, TCF4 and phospho-GSK-3β expression
was revealed in AC (Figure 6E-H), thus demonstrating the
pathway activation. Their expression did not change in NS. 
Immunocytochemistry. The immunocytochemical expression
patterns of the key molecules studied confirmed the
observations obtained by immunofluorescence (Figure 6I and
J). In NS, β-catenin expression was also clearly appreciable
as a nuclear staining (Figure 6K). TCF4 was also positive in
the nuclei of AC (Figure 6L).
Relationships of WNT3a and β-catenin protein expression
with clinical and molecular features. The WNT3a and β-
catenin protein expression was not associated with sex,
patient age, tumor location or age at diagnosis in the whole
series of gliomas (p>0.05 for all categories). In contrast,
their expression was significantly associated with
glioblastomas compared to low-grade gliomas (p=0.0113
and p=0.0349, respectively for WNT3a and β-catenin).
The comparison of WNT3a and β-catenin expression with
typical genetic and epigenetic alterations of gliomas
[epidermal growth factor receptor (EGFR) gene amplification,
O6-methylguanine-DNA methyltransferase (MGMT) promoter
hypermethylation, isocitrate dehydrogenase 1/2 (IDH1/2),
tumor protein p53 (TP53), phosphatase and tensin homolog
(PTEN) and telomerase reverse transcriptase (TERT)
mutations], already published (44, 45), revealed a significant
association of WNT3a immunoreactivity with TERT promoter
mutations (p=0.0208).
Western blotting. Western blotting analysis of whole-cell
lysates from glioblastoma cell lines revealed clear bands at
approximately 40 kDa for WNT3a and 92 kDa for β-catenin.
The two proteins were expressed variably and more intensely
in NS than in AC (Figure 7A). Densitometric quantification
of the bands is shown in Figure 7B.
Upon fractionated extraction, nuclear expression of β-
catenin was detected in both NS and AC (Figure 7C). In
fractionated glioblastoma tissue extracts, β-catenin
expression was appreciable in the nuclei, although to a lesser
extent compared to cytoplasmic expression (Figure 7D).
CTNNB1 mutation analysis. Search for mutations in CTNNB1
exon 3 and in the adjacent splice sites was performed in all
malignant astrocytic tumor samples and glioblastoma cell
lines. Mutation analysis revealed genetic mutations neither in
tumor samples nor in glioblastoma cell lines. 
qRT-PCR. By qRT-PCR, the WNT3A expression level was
evaluated in 11 glioblastomas and six grade II-III tumor
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Figure 3. Wingless-type MMTV integration site family member 3a
(WNT3a) and β-catenin immunohistochemical expression with respect
to tumor type and histological malignancy grade.
specimens, in 24 glioblastoma cell lines (10 NS and 14 AC),
and in two normal nervous tissue samples. When available,
the analysis was performed on NS and AC developed from
the same primary tumor (n=4). A fold change in the relative
gene expression of more than two was regarded as evidence
of WNT3A up-regulation. 
WNT3A expression levels were significantly up-regulated
in glioblastomas (7/11, 63.6%) and in anaplastic
astrocytomas (2/2, 100%), with increasing fold change from
grade III to grade IV (Figure 8A). Variable and weak WNT3A
expression was detected in grade II and III astrocytic and
oligodendroglial tumors. Compared to the normal nervous
tissue, glioblastomas showed up-regulation of WNT3A level
up to 80-fold and grade II-III gliomas up to 9-fold. The up-
regulation rate observed in glioblastoma tumor specimens
was consistent with previous data from the Cancer Genome
Atlas portal, documenting WNT3A overexpression in 55% of
glioma samples (25). 
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Figure 4. Correlations among transcription factor 4 (TCF4), Ki-67/MIB-1 and cyclin D1 labeling indices (LIs). A: Glioblastoma. High nuclear
TCF4 expression in several tumor cells, ×200. B: Grade II oligodendroglioma. TCF4 intensely positive nuclei, ×400. C: Glioblastoma. Several
cyclin D1-positive nuclei in the same area as in (A), ×200. D: Several Ki-67/MIB-1-positive nuclei in the same area as in (A), ×200. E: Several Ki-
67/MIB-1-positive nuclei in the same area as in (B), ×400. F: Glioblastoma. Nuclei of proliferative endothelial cells with high TCF4 expression, as
indicated by arrows, ×400. All stained with 3,3' diaminobenzidine.
Figure 5. Correlation among transcription factor 4 (TCF4), Ki-67/MIB-1 and cyclin D1 labeling indices (LIs). A: Linear regression analysis between
TCF4 and Ki-67/MIB-1 LIs (r=0.761, p<0.0001). B: TCF4 and cyclin D1 LIs (r=0.739, p<0.0001). C: Cyclin D1 and KI-67/MIB-1 LIs (r=0.873,
p<0.0001).
In glioblastoma cell lines, WNT3A up-regulation was
detected in 8/24 (33.3%) cases, with a similar distribution in
NS (3/10, 30%) and AC (5/14, 35.7%) (Figure 8B). By
comparing NS and AC with the matched primary tumors,
WNT3A gene expression levels were equally up-regulated in
NS and in the primary tumor, and they were, generally, higher
in NS than in AC. The maximum fold change observed in the
CTO3 NS was in agreement with its high proliferative rate
(data not shown). WNT3A gene expression was undetectable in
the cell lines derived from WNT3A-negative primary tumors.
Higher relative fold changes were observed in AC obtained
from tumors that did not develop NS from primary cultures.
Weak WNT3A overexpression was found in 010627 NS,
whereas it was not detected in U87MG AC, as reported in
the literature (24, 25). In the two normal nervous tissue
samples, WNT3A was not expressed.
Survival analysis. The relationship of WNT3a and β-catenin
expression with OS was evaluated in a sub-group of 25 patients
including 16 glioblastomas, seven grade II and two grade III
gliomas. By univariate analysis, WNT3a (p=0.033) and
cytoplasmic or cytoplasmic/nuclear β-catenin (p=0.042)
expression were significantly associated with a worse prognosis
in the whole group of gliomas (Figure 9). The median survival
time was 16 months for WNT3a-negative cases and 10 months
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Figure 6. Immunofluorescence (IF) and immunocytochemistry (ICC) of glioblastoma stem cells. IF, Neurospheres: A: High cytoplasmic Wingless-type
MMTV integration site family member 3a (WNT3a) expression. B: High cytoplasmic β-catenin expression. C: High nuclear transcription factor 4
(TCF4) expression. D: Cytoplasmic phopsho-glycogen synthase kinase-3β (GSK-3β) expression. IF, Adherent cells: E: Very poor cytoplasmic WNT3a
expression. F: Negative β-catenin expression. G: Negative TCF4 expression. H: Positive phopsho-GSK-3β expression. IF, Adherent cells after 50
μM temozolomide treatment for 48 h: I: Positive cytoplasmic WNT3a expression. J: Positive cytoplasmic β-catenin expression. K: Nuclear and
cytoplasmic TCF4 expression. L: Poor cytoplasmic phopsho-GSK-3β expression. Nuclei were counterstained with 4',6-diamidino-2-phenylindole.
All ×400 magnification. ICC, Neurospheres: M: Cytoplasmic WNT3a expression. N: Cytoplasmic and nuclear β-catenin expression. O: Nuclear
TCF4 expression. ICC, Adherent cells: P: Prevailing nuclear TCF4 expression. All 3,3' diaminobenzidine, ×400 magnification.
for WNT3a-positive cases. Censored cases were 4/11 (36.4%)
for the former and 2/14 (14.3%) for the latter. This was expected
since WNT3a and β-catenin correlated with malignancy.
Discussion 
The canonical WNT/β-catenin signaling pathway plays a
pivotal role in tumorigenesis and progression of malignant
astrocytic gliomas (10-15), increases the expression of stem
cell genes (35-40), promotes the migratory and invasive
capacity of glioblastomas, and influences epithelial to
mesenchymal transition activators (16, 46-48). Our findings
are in line with these observations. 
The key step in the pathway is the cytoplasmic
stabilization of β-catenin and its translocation to the nucleus
to form a β-catenin/LEF/TCF complex that regulates the
transcription of multiple genes involved in cellular
proliferation, differentiation, survival and apoptosis, such as
FRA1, c-MYC, and cyclin D1. Importantly, the oncogenic
function of β-catenin primarily depends on its subcellular
localization, with its nuclear accumulation being responsible
for malignant progression (49). 
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Figure 7. Western blot analysis. A: Representative analysis of two independent experiments displaying Wingless-type MMTV integration site family member
3a (WNT3a) and β-catenin expression in whole-cell extracts from glioblastoma cell lines, cultured as neurospheres or adherent cells. B: Quantitative
analysis of WNT3a and β-catenin levels normalized to α-tubulin, showing higher amounts of the two proteins in neurospheres than adherent cells. C, D:
β-Catenin expression by western blotting analysis in cytosolic and nuclear extracts from glioblastoma cell lines and tumor tissues. 
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Figure 8. WNT3A expression levels by quantitative real-time polymerase chain reaction in gliomas and glioblastoma cell lines. A: Relative WNT3A
expression levels in glioma tumor samples of different types and histological malignancy grades. B: Relative WNT3A expression levels in a panel of
24 glioblastoma cell lines, cultured as neurospheres (NS) or adherent cells (AC). Reported values are the average ± standard deviation (SD) of at
least two independent experiments in triplicate.
In our series, we report on the aberrant pathway activation
in malignant astrocytic gliomas by demonstrating the
overexpression of the WNT3a ligand at both the protein and
mRNA level. At the same time, high protein expression
levels of β-catenin and TCF4 were detected in anaplastic
astrocytomas and glioblastomas, but not in diffuse
astrocytomas or oligodendrogliomas, compared to normal
nervous tissue. WNT3a, β-catenin and TCF4 expression was
prevalent in astrocytic than in oligodendroglial tumors with a
significant correlation with the histological malignancy
grade, as reported in the literature (10-13, 18, 19, 25, 26, 28).
Contrary to high-grade glioma, where the cytoplasmic
subcellular localization of β-catenin prevails, in low-grade
glioma, β-catenin expression is mainly limited to the cell
membranes, thus suggesting a more structural than
oncogenic function. 
In our material, immunohistochemical detection of
WNT3a was rather unsatisfactory, even though occasionally
positive on the cell membranes of high-grade gliomas.
However, WNT3A up-regulation was demonstrated by qRT-
PCR in nine out of 11 (81.8%) malignant astrocytic gliomas
and in eight out of 24 (33.3%) glioblastoma cell lines, as in
previous observations (23-25). On the other hand, in
agreement with the activation of the WNT/β-catenin pathway
in glioma progression, frequent aberrant promoter
hypermethylation of WNT pathway inhibitor genes has been
reported in malignant astrocytic gliomas, with secreted
frizzled-related protein (SFRP1, SFRP2) and naked (NKD2)
inhibitors prevailing in primary glioblastomas (40%) and
dickkopf (DKK1) inhibitor in secondary glioblastomas (50%)
(50). Another inhibitor of the pathway is the WNT inhibitory
factor 1 (WIF1) gene, epigenetically silenced in 75% of
glioblastomas (51-54).
One crucial point concerns the immunohistochemical
demonstration of the nuclear translocation of β-catenin. In
our series, in the absence of clear nuclear expression,
cytoplasmic immunopositivity for β-catenin was regarded as
indicative of WNT/β-catenin signaling pathway activation,
as for previous authors (14, 17). Indeed, the cytoplasmic
stabilization of β-catenin precedes the nuclear translocation
and the subsequent transcription of target genes. In
fresh/FFPE malignant astrocytic gliomas, nuclear or
nuclear/cytoplasmic positivity of β-catenin has been found
(10-14, 16, 19). In our experience, the scattered and rare
nuclear expression was always found in association with the
cytoplasmic expression. Technical problems may have
hampered the immunohistochemical detection of nuclear β-
catenin in FFPE tumor samples. As a matter of fact, western
blotting analysis successfully revealed β-catenin expression
in the nuclear fractions from fresh glioblastoma tumor
samples and glioblastoma cell lines. The nuclear
translocation of β-catenin in glioblastoma cell lines has
already been reported (11-13, 18, 19, 24-26), also in
medulloblastoma cell lines (55). 
In endothelial cells of MVPs, the cytoplasmic and
membranous expression of β-catenin was easily detectable. It
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Figure 9. Relationship of Wingless-type MMTV integration site family member 3a (WNT3a) and β-catenin expression with survival in glioma patients.
Kaplan–Meier survival curves for overall survival (OS) with respect to WNT3a expression (A) and subcellular localization of β-catenin expression
(B). M: membranous; C: cytoplasmic; N: nuclear.
has been already observed in proliferative endothelial cells
of glioblastomas and related to angiogenesis and cell
proliferation (56). Expression of TCF4 in nuclei of
endothelial cells is in line with this interpretation. TCF4-
positive nuclei of hyperplastic endothelial cells significantly
correlated with the Ki-67/MIB-1 LI.
TCF4 is the main effector of the WNT/β-catenin signaling
pathway in the control of gene regulation. At its maximum
immunostaining intensity, it statistically correlated with the
histological malignancy grade and with Ki-67/MIB-1 and
cyclin D1 LIs (11, 13, 26, 28). Therefore, it might be used
as a proliferative marker both in astrocytic and
oligodendroglial glioma. On the other hand, TCF4
expression levels correlated with V-AKT murine thymoma
viral oncogene homolog 1 and 2 (AKT1 and AKT2), both
direct target genes of TCF4. Down-regulation of β-
catenin/TCF4 activity thus inhibits glioma cell proliferation
and invasion in vitro and tumor growth in vivo (13). 
Phospho-GSK-3β and phospho-β-catenin, both
instrumental for the proteasomal degradation of β-catenin,
had a similar expression pattern, opposite to that for
oncogenic WNT3a and β-catenin, and inversely correlated
to histological grade.
Key components of the canonical WNT/β-catenin
signaling pathway are commonly affected by genetic
mutations in several cancer types (29). Thus, we focused on
the search for potential activating mutations in CTNNB1
exon 3 that encodes the N-terminal regulatory sequence of
β-catenin, containing the consensus phosphorylation sites
for GSK-3β, and reported as a frequent event in different
tumor entities. Unlike other malignancies, however, the
absence of CTNNB1 activating mutations excludes genetic
events as responsible for the oncogenic activation of β-
catenin in malignant astrocytic gliomas, as previously
observed (14, 31).
The WNT/β-catenin signaling may contribute to the
maintenance of stem cell-like properties, inhibition of
differentiation, radioresistance and development of an
invasive phenotype in glioma (35-37, 57). As a matter of
fact, the canonical WNT/β-catenin signaling is crucially
involved in embryonic development and controls stem cell
biology by inducing self-renewal of both embryonic stem
cells (ESCs) and adult stem cells (21, 58-60). NANOG,
octamer-binding transcription factor 4 (OCT4), SRY (sex
determining region Y)-box 2 (SOX2) and c-MYC,
transcriptional factors responsible for pluripotency and
self-renewal in ESCs, are all TCF4 target genes (61, 62).
The activity of c-MYC and cyclin D1 target genes is
promoted by the downstream modulator of the WNT/β-
catenin pathway Forkhead box M1 (FOXM1) (24). Knock-
down of FOXM1 and β-catenin in glioma stem cells
(GSCs) abolishes their self-renewal and tumor-initiation
abilities (34). 
A novel proto-oncogene, pleomorphic adenoma gene-like 2
(PLAGL2), induces activation of WNT receptors and ligands
and increases the accumulation of β-catenin. Enhanced
PLAGL2 expression by gene amplification strongly
suppresses differentiation of normal neural stem cells and
GSCs, while it promotes their self-renewal capacity (36).
Another gene regulating the WNT/β-catenin signaling in
glioma is paternally expressed gene 3 (PEG3), an imprinted
gene with a tumor -suppressor activity. Aberrant PEG3
promoter hypermethylation was significantly associated with
high-grade glioma. Low PEG3 expression increases β-catenin
expression and thus proliferation of GSCs (63). Consistently
with these observations, no wonder, therefore, that WNT3a
and β-catenin are variably expressed in NS and AC, more in
the former than in the latter, as demonstrated by
immunofluorescence, immunocytochemistry, western blotting
and qRT-PCR. The reduced expression of WNT3a and β-
catenin in AC is in line with their more differentiating
character. 
Furthermore, WNT/β-catenin pathway activity confers
chemoresistance to cancer stem-like cells in different tumor
types (64, 65), glioblastomas included (39, 40). In our series,
treatment with temozolomide induced activation of the
WNT/β-catenin pathway in AC, in line with previous
observations (25). Thus, the inhibition of the pathway may
represent a potential tool to enhance the response of GSCs
to temozolomide. 
Our findings also demonstrate that WNT3a and
cytoplasmic/nuclear β-catenin expression were significantly
associated with a worse prognosis in patients with malignant
glioma (12, 14, 17-19), as in other cancer types (66, 67).
WNT3a and β-catenin may thus be regarded as potential
prognostic factors in the entire group of gliomas. 
WNT3a and β-catenin expression was not associated with
any of the well-known genetic and epigenetic features of
gliomas, except for TERT promoter mutations. 
Finally, the canonical WNT/β-catenin signaling pathway
can be regarded as a stemness regulator and enhancer of cell
proliferation in gliomas, strongly associated with the
histological malignancy grade. 
Conclusion
The canonical WNT/β-catenin signaling pathway contributes
to tumorigenesis and progression of malignant astrocytic
gliomas and promotes stem cell properties. TCF4 activates
transcription of target genes and significantly correlates with
the Ki-67/MIB-1 LI. The crucial point in the pathway is the
nuclear translocation of β-catenin.
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